The British-Swedish drugmaker has already withdrawn its EU marketing authorisation for the vaccine, branded Vaxzevria since ...

An intranasal formulation of AstraZeneca's widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a strong ...

Vaxzevria added almost $4 billion to its revenues last year, including $1.8 billion in the last quarter alone, but sales are expected to fall off in the coming year by a "low-to-mid twenties ...

On April 30, AstraZeneca admitted that the vaccine, sold under the name Vaxzevria, can cause fatal blood clots and low platelet counts, also known as thrombosis syndrome with thrombocytopenia ...

The company also announced its decision to revoke the vaccine Vaxzevria's marketing authorisations within Europe, noting that the oversupply has reduced the demand for Vaxzevria, which is no ...

Similar applications will be submitted in the UK and other nations in the coming months that have given a go-ahead to the vaccine, known as Vaxzevria. In recent months, Vaxzevria has come under ...

India's Serum Institute is sitting on a stockpile of half a billion doses of Covishield, the local version of AstraZeneca's Vaxzevria jab, the firm's CEO Adar Poonawalla told CNBC-TV18.

In the fourth quarter of 2024, we expect to announce updated data from the VTP-300 program in ongoing clinical trials in chronic hepatitis B at AASLD – The Liver Meeting® 2024 scheduled from November ...

The certificate is currently for EU citizens only. Covishield is the Indian-made version of AstraZeneca's Vaxzevria jab, which has been authorised in the EU. The vaccines currently eligible for ...

Alongside the EU withdrawal, similar applications are set to be filed UK and other countries that had approved the vaccine, ...

as a result of prior commercial sales of Vaxzevria® by AstraZeneca. We expect that this additional cash, when received, will enable us to fund our research and development plans further into the ...